Topical Ruxolitinib Therapeutic Cheat Sheet
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT …
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … Continue reading "Topical Ruxolitinib Therapeutic Cheat Sheet"
Following numerous office-based dermatologic procedures, erythema, swelling, and scarring are often feared complications experienced by our patients. Understanding the wound healing response is synonymous with understanding the stages of healing and ultimately the clinical appearance of each wound. Possessing and sharing a firm grasp on this knowledge allows for patient empowerment during the woun … 
The November 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on lasers, light sources, and devices featuring the perfect mix original articles, case reports, letters to the editor, and brief communications. Straight from the Editor’s desk, check out this month’s issue highlights.
ORIGINAL ARTICLES
Interventions to Minimize Pain During Photodynamic Therapy With 5-Aminolevulini … 
Perifolliculitis capitis abscedens et suffodiens or dissecting cellulitis (DC) is a rare and chronic disease with a predilection for the occipital, vertex, and parietal scalp. DC is characterized by multinodular lesions with purulent drainage and sinus tract formation. It is classically seen in middle-aged males of African descent. The etiology of the disease is unknown; however, leading theories … 
Intravenous immune globulin (IVIG) is a concentrate of pooled immunoglobulins derived from plasma donors. Its unique mechanism of action expands the utility of the medication to a variety of conditions. We continue our series, Therapeutic Cheat Sheet, with a closer look at IVIG, which is FDA-approved for the treatment of dermatologic conditions including dermatomyositis, Kawasaki disease, ITP, and … 